Advertisement

European Journal of Clinical Pharmacology

, Volume 73, Issue 6, pp 751–758 | Cite as

Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia—a restraint to the potentiality for signal detection

  • Lorraine Plessis
  • Ainhoa Gómez
  • Núria García
  • Gloria Cereza
  • Albert Figueras
Pharmacoepidemiology and Prescription

Abstract

Purpose

The aim of this study is to analyze the quality of the information contained in the adverse drug reactions (ADR) reports and to describe the magnitude and characteristics of the lacking information.

Methods

All reports of serious ADR received by the Catalan Center of Pharmacovigilance in 2014 were analyzed using the VigiGrade and a more clinical and qualitative approach.

Results

Up to 824 reports describing serious ADR were included in the study; of them, 503 (61.0%) were sent by health care professionals (HPs) and the remaining 321 (39.0%) came from pharmaceutical companies (PhC). More than 80% of missing variables such as ‘onset date’ or ‘time-to-onset’ of the ADR were from PhCs reports. ‘Onset of treatment date’ was not filled in 28 (22.2%) of the reports including an ‘additional monitoring’ medicine, and ‘end of treatment’ date was not completed in 53 of those reports (42.1%). In summary, 39% of the reports involving a black triangle medicine sent by PhCs lacked some essential information such as the onset date of treatment.

Conclusions

More than one third of the reports coming from manufacturers did not include information that is considered a limiting factor to evaluate any causal relationship, and can be an issue for the detection of safety signals. To take advantage of this huge amount of potentially important information that is almost useless at present, data mining tools and new algorithms should be developed and tested with the aim of finding formulas to deal with a huge amount of low quality data without losing it, nor generating a number of false associations.

Keywords

Pharmacovigilance Pharmaceutical industry Database Data mining 

Notes

Acknowledgements

This work was supported in part by the Departament de Salut de la Generalitat de Catalunya, a government institution of Catalonia.

Contributions of authors

Lorraine Plessis designed the initial study protocol, retrieved and selected the reports, analyzed and discussed the results and prepared the first draft of the manuscript.

Ainhoa Gómez contributed to the data analyses and prepared tables for the discussion of results. She also participated in the discussion of the manuscript draft, and improved the last version of the manuscript.

Núria Garcia trained LP in the use of the FEDRA Database, contributed to the data analyses and prepared tables for the discussion of results. She also participated in the discussion of the manuscript draft, and improved the last version of the manuscript.

Gloria Cereza participated in the design of the study protocol, coordinated the meetings to discuss the assessment of the included reports, indicated the results to be included in the manuscript and actively participated in the first draft review.

Albert Figueras proposed the idea of the study, contributed to the study protocol, participated in the general results discussions and reviewed the second draft of the manuscript and prepared the final draft.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Wysowski DK, Swartz L (2005) Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med 165:1363–1369CrossRefPubMedGoogle Scholar
  2. 2.
    Carpenter D, Zucker EJ, Avorn J (2008) Drug-review deadlines and safety problems. N Engl J Med 358:1354–1361CrossRefPubMedGoogle Scholar
  3. 3.
    Onakpoya IJ, Heneghan CJ, Aronson JK (2015) Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Med 13:26. doi: 10.1186/s12916-015-0270-2 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Aagaard L, Soendergaard B, Stenver DI, Hansen EH (2008) Knowledge creation about ADRs—turning the perspective from the rear mirror to the projector? Br J Clin Pharmacol 65:364–376CrossRefPubMedGoogle Scholar
  5. 5.
    Härmark L, van Grootheest AC (2008) Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 64:743–752CrossRefPubMedGoogle Scholar
  6. 6.
    Grundmark B, Holmberg L, Garmo H, Zethelius B (2014) Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol 70:627–635CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lindquist M (2008) VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42:409–419Google Scholar
  8. 8.
    Lindquist M (2003) Seeing and observing in international pharmacovigilance: achievements and prospects in worldwide drug safety. Uppsala Monitoring Centre, UppsalaGoogle Scholar
  9. 9.
    Bergvall T, Norén GN, Lindquist M (2014) vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37:65–77CrossRefPubMedGoogle Scholar
  10. 10.
    Karch FE, Lasagna L (1977) Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 21:247–254CrossRefPubMedGoogle Scholar
  11. 11.
    European Medicines Agency (2014) Guideline on good pharmacovigilance practices (GVP) Module VI. EMA http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf. Accessed 7 Dec 2016
  12. 12.
    BOE (2007) Real Decreto 1344/2007, de 11 de Octubre, por el que se regula la farmacovigilancia de los medicamentos de huso humano. Boletin oficial del Estado http://www.boe.es/boe/dias/2007/11/01/pdfs/A44631-44640.pdf. Accessed 7 Dec 2016
  13. 13.
    European Medicines Agency-Medicines under additional monitoring (2016) List of medicines under additional monitoring. EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp. Accessed 7 Dec 2016
  14. 14.
    Sempere E, Palop V, Bayón A, Sorando R, Martínez-Mir I (2006) Calidad de la publicación de reacciones adversas a medicamentos en la sección de Cartas al Director de cuatro revistas españolas de medicina interna y medicina general. Aten Primaria 37:187–193CrossRefPubMedGoogle Scholar
  15. 15.
    Tuccori M, Giustarini G, Blandizzi C et al (2013) Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance. J Public Health 21:365–372CrossRefGoogle Scholar
  16. 16.
    Faillie JL, Robin P, Bres V, Pinzani V, Bos-thompson MA, Hillaire-buys D (2013) The Athe score: a new quality score for spontaneous adverse drug reaction reports. Fundam Clin Pharmacol 27:106–107Google Scholar
  17. 17.
    McCarthy M (2015) Drug makers’ adverse event reports are often incomplete, US report finds. Br Med J 350:651. doi: 10.1136/bmj.h651 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Catalan Pharmacovigilance CenterBarcelonaSpain
  2. 2.Clinical Pharmacology ServiceUniversity Hospital Vall d’HebronBarcelonaSpain
  3. 3.Fundació Institut Català de FarmacologiaUniversity Hospital Vall d’Hebron, P. Vall d’HebronBarcelonaSpain
  4. 4.Departament de Farmacologia, de Terapèutica i de ToxicologiaUniversitat Autònoma de BarcelonaBarcelonaSpain

Personalised recommendations